I-New Delhi: Ephendula isiphakamiso se-Fresenius Medical Care, iKomidi Lochwepheshe Abakhethekile (i-SEC) le-Central Drugs Standard Control Organisation (i-CDSCO) lincome inkampani ukuthi ithumele isizathu sokuvunyelwa kanye nedatha yesivivinyo somtholampilo sesigaba sesi-3 se-calcium chloride dihydrate kanye nedatha yokuqapha ngemuva kokumaketha evela emazweni avunyelwe ukuze kucatshangelwe kabanzi.
Le nkampani ngaphambilini yafaka isicelo sokukhiqiza nokuthengisa isixazululo se-calcium chloride dihydrate esilinganisweni esingu-100 mmol/L, esisetshenziselwa “ukwelashwa kokufaka i-calcium esikhundleni sokwelashwa kokufaka i-renal replacement therapy (CRRT), i-continuous low-efficiency (daily) dialysis (CLED) kanye ne-therapeutic plasma exchange (TPE) ene-citrate anticoagulation. Lo mkhiqizo ulungele abantu abadala nezingane” futhi washo izizathu zokukhishwa ezivivinyweni zemitholampilo zesigaba III kanye nesigaba IV.
Ikomidi liphawule ukuthi lo mkhiqizo uvunyiwe emazweni aseYurophu njengePortugal, i-United Kingdom, iBrazil, iSwitzerland, iFrance kanye neDenmark.
I-calcium chloride dihydrate ehlanganisiwe yi-CaCl2 2H2O, okuyi-calcium chloride equkethe ama-molecule amabili amanzi ngeyunithi ngayinye ye-calcium chloride. Kuyi-crystalline ecwebezelayo emhlophe, encibilika kalula emanzini futhi e-hygroscopic, okungukuthi ekwazi ukumunca umswakama ovela emoyeni.
I-calcium chloride dihydrate iyinhlanganisela engasetshenziswa njengohlelo lokuncibilikisa i-chitin uma incibilikiswa ku-methanol. Idlala indima ebalulekile ekuphuleni isakhiwo sekristalu se-chitin futhi inezinhlobo eziningi zezicelo emkhakheni wekhemistri.
Emhlanganweni we-SEC Nephrology owawubanjwe ngoMeyi 20, 2025, iphaneli ibuyekeze isiphakamiso sokuvumela ukukhiqizwa nokumaketha kwesisombululo sokufakwa kwe-calcium chloride dihydrate esingu-100 mmol/L ukuze sisetshenziswe “ekwelashweni kokushintsha kwe-calcium ekwelashweni kokushintsha kwezinso okuqhubekayo (CRRT), i-dialysis eqhubekayo ephansi (yansuku zonke) (i-SLEDD), kanye ne-thrapeutic plasma exchange (TPE) ene-citrate anticoagulation. Lo mkhiqizo ukhonjiswa kubantu abadala nasezinganeni” futhi wanikeza izizathu zokukhululwa ezivivinyweni zemitholampilo zesigaba III nese-IV.
Ngemva kwengxoxo eningiliziwe, ikomidi lincome ukuthi isisekelo sokuvunyelwa, kanye nedatha yesivivinyo sezokwelapha sesigaba sesi-3 kanye nedatha yokuqapha ngemuva kokumaketha evela emazweni avumile umuthi, kuthunyelwe ekomidini ukuze kucutshungulwe kabanzi.
Funda futhi: I-CDSCO Group Igunyaze Ukulebula Okubuyekeziwe kwe-Sanofi's Myozyme, Icela Ukubuyekezwa Kwemithetho
UDkt. Divya Kolin ungumfundi ophothule ePharmD onolwazi oluningi lwezokwelapha kanye nolwesibhedlela kanye namakhono amahle kakhulu okuxilonga nokwelapha. Usebenze futhi njengosokhemisi we-oncology emnyangweni we-oncology eMysore Medical College and Research Institute. Njengamanje uphishekela umsebenzi wakhe ocwaningweni lwezokwelapha kanye nokuphathwa kwedatha yezokwelapha. Ubesebenza neMedical Dialogue kusukela ngoJanuwari 2022.
       Dr Kamal Kant Kohli, MBBS, MD, CP, is a thoracic specialist with over 30 years of experience and specializes in clinical writing. He joins Medical Dialogues as the Editor-in-Chief of Medical News. Apart from writing articles, as the Editor, he is responsible for proofreading and reviewing all medical content published in Medical Dialogues, including content from journals, research papers, medical conferences, guidelines, etc. Email: drkohli@medicaldialogues.in Contact: 011-43720751
Ucwaningo lwe-ABYSS luthole ukuthi ukuyeka ama-beta-blocker ngemuva kokuhlaselwa yinhliziyo kuholele ekukhuphukeni komfutho wegazi, izinga lokushaya kwenhliziyo, kanye nemicimbi emibi yenhliziyo: …